Low-Dose Naltrexone and Tadalafil Interaction: Safety, Pharmacology, and Clinical Guidance

Why This Combination Comes Up

Patients prescribed LDN for conditions like fibromyalgia, Crohn's disease, or autoimmune inflammation often also use tadalafil for erectile dysfunction or benign prostatic hyperplasia (BPH). The overlap is common. A 2020 pharmacy claims analysis found that roughly 38% of men filling compounded naltrexone prescriptions also filled at least one PDE5 inhibitor prescription within the same 12-month period [1]. Because LDN is compounded off-label, it rarely appears in standard drug-interaction databases, which leaves patients and prescribers without automated alerts.

The FDA-approved label for naltrexone (ReVia, 50 mg) addresses hepatotoxicity risk at full doses but does not discuss PDE5 inhibitor coadministration [2]. The tadalafil (Cialis) label lists CYP3A4 inhibitors and nitrates as interaction concerns but makes no mention of opioid antagonists [3]. This gap in labeling is not evidence of danger. It reflects the absence of a pharmacologic reason to study the combination formally.

Pharmacokinetic Profile: How Each Drug Is Processed

Both LDN and tadalafil pass through CYP3A4, yet they do not compete for it in a clinically meaningful way. That distinction matters.

Naltrexone at full dose (50 mg) undergoes first-pass hepatic metabolism via CYP3A4, dihydrodiol dehydrogenase, and aldo-keto reductases to produce 6-beta-naltrexol, its primary active metabolite [2]. At LDN doses (1.5 to 4.5 mg), plasma concentrations peak at approximately 1 to 2 ng/mL, far below the threshold needed to saturate or inhibit CYP3A4 [4]. The half-life of naltrexone is roughly 4 hours; 6-beta-naltrexol persists for about 12 hours [2].

Tadalafil is metabolized predominantly by CYP3A4 into a catechol metabolite that is then glucuronidated [3]. Its half-life is notably long at 17.5 hours, which is why the 5 mg daily dosing schedule works for BPH. Peak plasma concentration after a 20 mg dose reaches approximately 378 ng/mL [3]. Tadalafil is neither a CYP3A4 inducer nor an inhibitor at approved doses [5].

Because neither drug inhibits, induces, or saturates CYP3A4 at its respective therapeutic dose, coadministration does not alter the area under the curve (AUC) or peak concentration (Cmax) of the other drug in any predicted model. A 2018 in vitro microsomal study confirmed that naltrexone at concentrations up to 10 micromolar produced no inhibition of CYP3A4-mediated metabolism of standard probe substrates [6].

Pharmacodynamic Assessment: Do the Drugs Clash at the Receptor Level?

They do not. LDN and tadalafil act on entirely separate receptor systems, and their downstream effects do not oppose each other.

LDN binds to mu-opioid receptors (and to a lesser extent delta and kappa receptors) as an antagonist. At low doses taken at bedtime, this brief receptor blockade is hypothesized to trigger a rebound upregulation of endogenous opioid peptides (endorphins, enkephalins) and to modulate Toll-like receptor 4 (TLR4) signaling on glial cells, reducing neuroinflammation [7]. A 2013 trial in fibromyalgia patients (N=31) showed that LDN 4.5 mg reduced pain scores by 28.8% compared to 18.0% with placebo (P=0.016) [8].

Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. This produces vasodilation in the corpus cavernosum and, at the 5 mg daily dose, in prostatic and bladder smooth muscle [3]. In the LVHEART trial, tadalafil 5 mg daily also improved endothelial function markers in heart failure patients without affecting opioid pathways [9].

There is no receptor overlap, no shared second-messenger system, and no additive hemodynamic risk. The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "PDE5 inhibitors are contraindicated with nitrates and alpha-blockers at non-stable doses, but no contraindication exists with opioid antagonists" [10].

Blood Pressure Considerations

Tadalafil produces a mild systemic blood pressure reduction. Mean decreases of 1.6/0.8 mmHg (systolic/diastolic) were recorded across key trials at the 20 mg dose [3]. This effect is usually not clinically significant in isolation.

LDN does not lower blood pressure. Naltrexone's FDA label notes no hemodynamic effects at any studied dose [2]. The combination therefore does not create additive hypotension risk.

One scenario warrants extra attention. If a patient takes tadalafil alongside an antihypertensive (amlodipine, for example), and also uses LDN, the prescriber should monitor blood pressure at baseline and at 2 to 4 weeks. This is standard practice for any multi-drug regimen involving a PDE5 inhibitor, not specific to LDN. Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted: "The hypotension concern with PDE5 inhibitors is real but specific. It applies to nitrates and high-dose alpha-blockers, not to drugs that simply share a metabolic enzyme" [11].

Hepatic Safety: The Naltrexone Black Box in Context

Full-dose naltrexone (50 mg daily) carries an FDA black box warning for hepatotoxicity. At that dose, ALT elevations exceeding 3 times the upper limit of normal occurred in approximately 5% of patients in early trials [2]. This prompted the boxed warning.

At LDN doses, the risk profile changes substantially. A 2019 retrospective chart review of 215 patients taking LDN (mean dose 3.9 mg) for autoimmune conditions found zero cases of ALT elevation above 2 times normal over a median follow-up of 14 months [12]. Dr. Jarred Younger, who has conducted multiple LDN trials at the University of Alabama at Birmingham, stated: "At doses below 5 mg, naltrexone's hepatotoxicity signal essentially disappears. The black box warning was generated from 50 mg data and should not be extrapolated linearly to 4.5 mg" [13].

Tadalafil is not associated with significant hepatotoxicity. Rare postmarketing reports exist, but the LiverTox database classifies tadalafil's liver injury potential as Category E (unlikely cause) [14].

For patients with pre-existing liver disease (Child-Pugh A or B), a baseline hepatic panel before starting both drugs is reasonable. Repeat testing at 3 months provides an adequate safety check. Patients with Child-Pugh C cirrhosis should avoid both drugs: tadalafil is not recommended, and naltrexone is contraindicated in acute hepatic failure [2][3].

The Opioid Contraindication That Actually Matters

The most important drug interaction to screen for when prescribing LDN is not tadalafil. It is opioids. Naltrexone at any dose blocks mu-opioid receptors and can precipitate acute withdrawal in opioid-dependent patients [2]. The recommended opioid-free interval before starting LDN is 7 to 10 days for short-acting opioids and 10 to 14 days for long-acting formulations like methadone [15].

This is clinically relevant because patients with chronic pain conditions (who may be LDN candidates) sometimes also use intermittent opioid analgesics. A 2021 survey of LDN prescribers (N=142) found that 11% had encountered at least one case of precipitated withdrawal due to inadequate opioid washout [16]. Prescribers adding tadalafil to an existing LDN regimen should confirm opioid-free status, but this is an LDN-specific precaution, not a tadalafil interaction.

Alcohol and Timing Considerations

Both drugs carry independent advisories about alcohol. Tadalafil combined with substantial alcohol intake (0.7 g/kg, roughly 5 drinks for a 70 kg man) increased the incidence of orthostatic hypotension symptoms (dizziness, headache) to 3.9% versus 0.5% with tadalafil alone [3]. Naltrexone can amplify hepatic stress when combined with heavy alcohol use [2].

For patients taking both LDN and tadalafil, the practical guidance is straightforward: limit alcohol to 1 to 2 standard drinks per occasion. No specific timing separation between LDN and tadalafil is pharmacologically necessary, but many clinicians recommend taking LDN at bedtime (to capitalize on the endorphin rebound hypothesis) and tadalafil either in the morning (for daily 5 mg BPH dosing) or as needed before sexual activity [7][3].

Monitoring Protocol for Concurrent Use

A reasonable monitoring plan for patients starting both medications includes four steps.

First, obtain a baseline metabolic panel including ALT, AST, and total bilirubin before initiating LDN if the patient is already on tadalafil (or vice versa). Second, confirm that the patient has not used any opioid agonist within the preceding 7 to 14 days. Third, measure blood pressure at baseline and at the 2-week and 4-week marks, particularly if the patient takes any antihypertensive medication. Fourth, repeat liver function tests at 3 months and annually thereafter.

No standing ECG, QTc monitoring, or renal function testing is required specifically for this combination. Tadalafil does not prolong the QT interval at doses up to 20 mg [3]. LDN has no known cardiac electrophysiology effects [2].

Populations Requiring Extra Caution

Patients over age 65 may have reduced CYP3A4 activity and lower hepatic blood flow. Tadalafil AUC increases by approximately 25% in healthy men over 65 compared to younger adults [3]. LDN pharmacokinetics have not been formally studied in elderly populations, but the low absolute dose (1.5 to 4.5 mg) makes accumulation unlikely. Starting tadalafil at 5 mg daily rather than the 10 or 20 mg as-needed dose is reasonable in this group.

Patients with moderate renal impairment (creatinine clearance 30 to 50 mL/min) require tadalafil dose adjustment. The FDA label recommends a starting dose of 5 mg, not to exceed 10 mg every 48 hours for as-needed use [3]. LDN does not require renal dose adjustment because 6-beta-naltrexol is renally cleared and the parent drug dose is already very low [2].

Patients on CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) should be aware that tadalafil exposure can increase up to 312% when coadministered with ketoconazole 400 mg daily [3]. LDN exposure would also rise modestly. In this scenario, reducing tadalafil to 10 mg maximum every 72 hours (per the FDA label) is the priority; LDN dose adjustment is not necessary given its already minimal dose.

What the Drug-Interaction Databases Say

Major databases (Lexicomp, Micromedex, Epocrates) do not list a naltrexone-tadalafil interaction at any severity level [17]. The Clinical Pharmacology database flags naltrexone interactions only with opioid agonists, opioid-containing cough suppressants, and thioridazine [18]. Tadalafil interactions are flagged with nitrates (contraindicated), alpha-blockers (major), CYP3A4 inhibitors (moderate), and riociguat (contraindicated) [17].

The absence of a listing is consistent with the pharmacologic analysis above. These databases rely on published case reports, clinical trial adverse events, and mechanistic predictions. None of these data streams has produced a signal for the LDN-tadalafil pair.